The Medicines Company recent said it will be presenting data on its antimicrobial products and late-state product candidates at the 27th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017) on April 22-25 in Vienna, Austria.
“The scope and diversity of the research being presented at ECCMID 2017 provides evidence of The Medicines Company’s strong commitment to advancing the discovery and development of innovative antimicrobial drugs for pathogens that the World Health Organization recently identified as a critical need,” Michael Dudley, The Medicines’ Company senior vice president and head of R&D, said in a release.
The company plans to present data from the TANGO 1 trail comparing its investigational antibiotic meropenem-vaborbactam to piperacillin-tazobactam in treating complicated urinary tract infections, as well as experimental treatment model data on Orbactiv (oritavancin) and Minocin (minocycline) for Injection.
“With The Medicines Company’s infectious disease franchise we have a fully-integrated biopharmaceutical company with capabilities from discovery to commercialization,” The Medicines Company President and Chief Operating Officer Tony Kingsley said in the release. “We are tackling major antibacterial threats which we also believe represent attractive global market opportunities. We are committed to growing this focused, effective, and fully- integrated infectious disease business.”